Loading comparison data...
Compare ALIROCUMAB (Praluent) and Evolocumab (Repatha) — clinical data, side effects, and patient experiences.
Praluent · PCSK9 Inhibitor
How it works
12.1 Mechanism of Action Alirocumab is a human monoclonal antibody that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein (...
Approved for
Repatha · PCSK9 Inhibitor
How it works
Human monoclonal antibody that binds to PCSK9, preventing LDL receptor degradation and increasing LDL-C clearance.
Approved for
Estimated frequency (%) based on clinical trial data
No specific warnings
Based on 4 Reddit discussions
ALIROCUMAB
0%
positive
0 threads
Evolocumab
0%
positive
4 threads
% of discussions mentioning each side effect
No community discussions found for ALIROCUMAB yet.
4 Reddit threads analysed for Evolocumab
Overall Sentiment
Mixed
Comparison Threads
0
Avg Post Score
11 upvotes
Most discussed side effects in community
Hi everyone, I’m an OBGYN SR 🙋♀️ seeking some practical guidance regarding Repatha (evolocumab) access in India for my father. He is a 64-year-old male who recently underwent left main coronary stenting and is currently on maximally tolerated medical therapy (rosuvastatin + ezetimibe + DAPT etc).
I've been diagnosed with 2 soft plaques (one in my heart at 35% stenosis and one in my right carotid at 45% stenosis) back in early July. Calcium score is 0. My cardiologist immediately put me on Rosuvastatin+Ezetimibe 20+10, Colchicine 1mg and Aspirin 100mg; I was taking them religiously for 8 week
About 8 weeks ago I (M, 50), started with 5mg Rosuvastatin due to an LDL cholesterol level of >160 and a scan of my neck vessels showing first signs of atherosclerosis. Before, I tried different diet changes, with no results larger than a 10% drop. After 4 weeks of just 5mg Rosuva my LDL came
Hi everyone, I’m an OBGYN SR 🙋♀️ seeking some practical guidance regarding Repatha (evolocumab) access in India for my father. He is a 64-year-old male who recently underwent left main coronary stenting and is currently on maximally tolerated medical therapy (rosuvastatin + ezetimibe + DAPT etc).
Community discussions are sourced from public Reddit threads. Content reflects individual opinions and is not medical advice.
Both ALIROCUMAB and Evolocumab belong to the PCSK9 Inhibitor class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. ALIROCUMAB is administered via Subcutaneous, whereas Evolocumab uses Oral. Route of administration can affect onset of action and patient adherence.
ALIROCUMAB carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.
Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.